Emmaus Life Sciences signs option deal with Cedars-Sinai to evaluate L-glutamine in pancreatic cancer trial

PUBT · 1d ago
Emmaus Life Sciences signs option deal with Cedars-Sinai to evaluate L-glutamine in pancreatic cancer trial
  • Emmaus Life Sciences entered an exclusive option agreement with Cedars-Sinai to evaluate L-glutamine with chemotherapy for pancreatic ductal adenocarcinoma.
  • Results were already presented via publication of the GlutaPanc trial in Nature Cancer.
  • Work will assess whether the combination can improve treatment outcomes for pancreatic cancer patients, with safety and efficacy not yet established.
  • The agreement signals a strategic push beyond sickle cell disease into oncology, with regulatory approval for this use not assured.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608310930BIZWIRE_USPR_____20260831_BW760299) on August 31, 2026, and is solely responsible for the information contained therein.